"Morning sickness" is a misleading name. Here is the real pattern

NVP typically begins between weeks 4 and 6 of pregnancy, coinciding with the rapid rise in hCG. Symptoms usually peak at weeks 8 to 10 and resolve for most people by weeks 12 to 14. However, approximately 20 to 23% of people continue to experience symptoms beyond week 14, and a smaller minority have symptoms into the third trimester. The range of normal is wide, and persistence of symptoms does not indicate a problem with the pregnancy.

NVP is associated with lower rates of miscarriage in multiple studies. A 2016 meta-analysis found a roughly 70% lower risk of miscarriage among women who experienced NVP compared with those who did not. However, the absence of nausea does not indicate an unhealthy pregnancy. Many people have entirely symptom-free pregnancies and carry to term without any difficulty. The association between nausea and lower miscarriage risk is a population-level finding, not a diagnostic indicator for any individual pregnancy.

Severe NVP involves frequent vomiting that is distressing but does not necessarily cause dehydration, significant weight loss, or inability to function. Hyperemesis gravidarum is a clinical condition characterised by persistent vomiting leading to weight loss of more than 5% of pre-pregnancy body weight, dehydration, and electrolyte imbalance. HG typically requires hospitalisation for intravenous fluids and antiemetic medication. If you cannot keep fluids down for more than 24 hours, are feeling faint, or have lost significant weight, contact your midwife or doctor promptly. The RCOG Green-top Guideline No. 69 provides the current clinical management framework.

Hyperemesis gravidarum (HG) is a severe form of pregnancy nausea and vomiting characterised by persistent vomiting, inability to keep fluids down, weight loss of 5% or more of pre-pregnancy body weight, and electrolyte imbalance. It affects approximately 0.3 to 3% of pregnancies, with most estimates clustering around 1.1% in large population studies. Researcher Marlena Fejzo at the University of Southern California has been central to identifying its genetic and hormonal basis, documenting in multiple papers that HG is systematically under-treated and under-recognised, with many sufferers spending weeks vomiting multiple times daily before receiving appropriate antiemetic or intravenous therapy. HG can require hospitalisation and, in severe cases, affects pregnancy continuation decisions.

Growth differentiation factor 15 (GDF15) is a hormone produced by the placenta during pregnancy that acts on receptors in the brainstem to suppress appetite and trigger nausea and vomiting. A landmark 2023 study published in Nature by Fejzo et al., involving data from over 53,000 women, found that GDF15 levels are the primary driver of NVP severity, and that women with lower pre-pregnancy baseline GDF15 levels are more severely affected when the placenta floods the system with the hormone. The Cambridge group also found that women whose fetuses carry a gene variant producing higher GDF15 experience more severe nausea, demonstrating a direct paternal contribution to the mother's NVP experience through the fetus's genetics. This discovery has significant treatment implications, as desensitisation approaches targeting the GDF15 receptor are being explored.

Several clinical factors are reliably associated with more severe NVP. Carrying a female fetus is associated with higher HCG levels and marginally increased NVP severity across multiple studies. First pregnancies tend to be associated with more severe symptoms than subsequent pregnancies, possibly because physiological adaptation occurs with repeated exposure. Women with a personal or family history of motion sickness, migraines, or HG in a prior pregnancy face significantly elevated risk of severe symptoms. A history of nausea when taking oestrogen-containing contraceptives also predicts greater susceptibility. The 2023 Fejzo Nature study added that lower baseline GDF15 levels before conception are a measurable biological risk factor, with women who had the lowest quartile of pre-conception GDF15 at greatest risk of HG.

A treatment ladder is recommended in both RCOG and ACOG guidelines, starting with conservative measures and escalating based on severity. Ginger supplementation (250mg four times daily) has the strongest evidence among non-pharmacological approaches, with a 2014 Cochrane review finding it superior to placebo in reducing nausea scores. Vitamin B6 (pyridoxine, 10 to 25mg three times daily) is a first-line pharmacological option, commonly combined with doxylamine (an antihistamine) under the brand name Bonjesta in the US and Diclectin in Canada. Ondansetron (a 5-HT3 antagonist originally developed for chemotherapy-induced nausea) is widely used for more severe cases, though prescribing guidance varies internationally due to limited first-trimester safety data. Intravenous fluids and corticosteroids are used in HG cases requiring hospitalisation.

NVP is associated with a lower risk of miscarriage at the population level, though this association does not allow predictions for individual pregnancies. A 2016 meta-analysis published in JAMA Internal Medicine (Hinkle et al., N=797 pregnancies from the PRISM cohort) found that women with NVP had a 50 to 75% lower risk of pregnancy loss compared to symptom-free women in the same cohort. The biological explanation is consistent with the HCG hypothesis: robust placental development drives both higher HCG levels and more pronounced symptoms. Conversely, the absence of nausea does not indicate miscarriage risk: many healthy pregnancies are entirely symptom-free. Nausea that suddenly stops before week 10 to 12 may warrant investigation if it was previously severe, but mild or absent symptoms throughout are within the normal range.

Yes, through the fetus. The 2023 Fejzo et al. Nature study demonstrated that fetal GDF15 genotype, which is determined 50% by paternal genetics, influences the severity of the mother's NVP. Fetuses carrying a variant that increases GDF15 production were associated with more severe maternal nausea. This is one of the first direct demonstrations of a paternal genetic contribution to a maternal pregnancy symptom. The mechanism is that the placenta, which is genetically half-paternal, produces GDF15 that acts on the mother's brainstem receptors. Fathers of children from a previously very nauseating pregnancy may therefore contribute to similarly severe NVP in subsequent pregnancies with different partners.

For mild to moderate NVP, nutritional impact is generally manageable. The fetus is protected by physiological priority during early pregnancy, and short-term maternal dietary restriction during the first trimester rarely causes fetal nutritional deficits in otherwise well-nourished women. However, in moderate to severe NVP, particularly where specific food aversions eliminate major food groups for weeks, micronutrient deficiencies including folate, iron, B12, and vitamin D can develop. In HG, significant maternal weight loss (over 5% of body weight) is associated with small-for-gestational-age infants and preterm birth in some studies. The RCOG Green-top Guideline No. 69 recommends monitoring weight, urine ketones, and electrolytes in any woman with persistent vomiting beyond the first trimester to identify cases requiring nutritional support.

All-day symptoms do not necessarily indicate greater severity, but they do correlate with higher PUQE (Pregnancy Unique Quantification of Emesis) scores, the validated clinical scoring tool used to classify NVP severity. The 2017 British Journal of General Practice study (N=256) found that 80% of women with NVP experienced symptoms at multiple times of day, and that all-day sufferers were more likely to seek medical consultation and to require antiemetic medication than those with morning-restricted symptoms. The terms "morning sickness" and "all-day sickness" describe timing, not inherently different underlying processes. Both are driven by the same hormonal mechanisms; the timing variation reflects individual differences in circadian cortisol rhythms, gastric emptying rates, and HCG sensitivity rather than a qualitatively different condition.